Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pfizer takes stake in gene-therapy specialist Vivet Therapeutics

by Lisa M. Jarvis
March 23, 2019 | A version of this story appeared in Volume 97, Issue 12

 

Adding to the flurry of gene-therapy deals, Pfizer has paid roughly $51 million for a 15% stake in Vivet Therapeutics, which is developing liver-directed gene therapies. Pfizer has an option to acquire the rest of Vivet after it unveils certain data on VTX-801, Vivet’s gene therapy for Wilson’s disease, which is caused by mutations in the gene encoding the ATP7B protein. So far in gene therapy this year, Biogen bought Nightstar Therapeutics, Roche acquired Spark Therapeutics, and Sarepta Therapeutics purchased Myonexus Therapeutics.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.